Drug Development Partnerships
The Leukemia & Lymphoma Society (LLS) partners with several organizations whose key resources and expertise can help accelerate the process of developing new drugs and making them available to patients.
By combining the resources of biotechnology and pharmaceutical companies, private-sector and public firms and academic institutions, we're able to see faster and more efficient results in the development of new drug therapies to benefit individuals with blood cancer.
Our Therapy Acceleration Program is one example of how the synergy of our partners is contributing to more rapid drug development.
Streamlining drug development to treat unmet medical needs is critical to achieving our mission to cure leukemia, lymphoma, Hodgkin's disease and myeloma and improve the quality of life of patients and their families. Our TAP partnerships now extend from late preclinical drug development programs to all phases of clinical trials.
If your company has a potential therapeutic breakthrough that you'd like to discuss with us, please contact Jun Xu at email@example.com.